Phase II Trial of Rituximab In Myasthenia Gravis
Diseases of the Nervous System
What is the purpose of this trial?
The specific primary aim of this study is to determine whether rituximab is a safe and beneficial therapeutic for MG that warrants further study in a phase III efficacy trial. The main secondary objective is to evaluate whether there is a trend toward clinical benefit as measured by MG-specific clinical outcome scales. If successful, measures studied would lay the groundwork toward optimizing the design of a subsequent phase III fficacy trial of rituximab in MG.
- Ages21 years and older
- Trial withNational Institute of Neurological Disorders and Stroke (NINDS)
- Start Date05/06/2014
- End Date12/30/2015
- Last Updated02/22/2018
- Study HIC#1401013253